Dying From Dengue Encephalitis in the Absence of DHF: A Case Report
Abstract
Background: Dengue fever is an endemic infectious disease in tropical countries including Sri Lanka with a seasonal transmission. Expanded dengue syndrome consists of unusual manifestations of dengue involving the liver, heart, kidney, and central nervous system. Dengue encephalitis is a rare neurological manifestation of expanded dengue syndrome which can lead to significant morbidity and mortality. Among patients with dengue encephalitis, rapid deterioration without plasma leakage and preceding neurological symptoms and signs is an unusual presentation.
Case presentation: We report an 18-year-old previously healthy male, who presented with fever for three days with mild frontal headache without other preceding neurological signs who succumbed following rapid deterioration and generalized tonic-clonic seizures complicated with status epilepticus despite optimal medical management. He did not have features of plasma leakage clinically and through focused ultrasound and did not have rising pack cell volume. He was positive for dengue NS1, IgM, and RT-PCR for dengue Serotype 3 with histopathological findings of the brain revealing dengue encephalitis.
Conclusions: Dengue encephalitis can lead to sudden and unexpected mortality associated with status epilepticus with or without signs of dengue hemorrhagic fever. It is a rare manifestation seen in dengue expanded syndrome and can cause sudden death without warning symptoms and signs. The initial presentation may have little…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.